OUR PROGRESS IN DEVELOPING A POTENTIAL COVID-19 VACCINE
In the fight against COVID-19, a vaccine is a critical part of addressing the global health crisis by decreasing rates of infection, disease and death worldwide. But today, there is no vaccine available. Pfizer and BioNTech are leveraging our decades of scientific expertise and working together to develop, test and manufacture a mRNA vaccine to help prevent COVID-19. The Phase 2/3 clinical trial began in late July, and participants 12 and over are now eligible to participate.
Developing a potential breakthrough vaccine to help prevent COVID-19 is only possible through the dedicated work of thousands of individuals and those who volunteer to take part in research. We are committed to diversity in our clinical trial and ensuring that individuals from communities that have been most affected by COVID-19 have the opportunity to participate.
We are grateful to each of the more than 130 clinical trial investigators and their study teams who are partnering with us in this effort and to all of the participants who have volunteered, and will volunteer, to help make a difference for society.
PHASE 2/3 TRIAL UPDATE